| Upcoming events on REGENERON PHARMACEUTICALS |
|
| 02/05/21 | | FY 2020 Earnings Release |
| 02/05/21 | 08:30am | | FY 2020 Earnings Call |
| 05/06/21 | | Q1 2021 Earnings Release (Projected) |
| 08/05/21 | | Interim 2021 Earnings Release (Projected) |
|
| Past events on REGENERON PHARMACEUTICALS |
|
| 01/11/21 | 08:20am | | JP Morgan Healthcare Conference |
| 12/07/20 | 04:30pm | | American Society of Hematology Meeting |
| 12/02/20 | 08:00am | | Piper Sandler Health Care Conference |
| 12/01/20 | 10:30am | | Evercore ISI HealthCONx Conference |
|
| Upcoming sector events for REGENERON PHARMACEUTICALS |
|
|
| |
|
| Past sector events for REGENERON PHARMACEUTICALS |
|
|
|
|
|
| Annual results | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 (e) |
Sales
M $ |
Released
Forecast
Spread | 4 104
4 177
-1,8% | 4 860
4 923
-1,3% | 5 872
5 788
1,5% | 6 711
6 520
2,9% | 7 863
7 816
0,61% |
8 494
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | 1 327
1 501
-12% | 1 435
1 470
-2,3% | 2 732
2 658
2,8% | 3 110
2 959
5,1% | 3 420
3 610
-5,3% |
4 158
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | 1 252
1 392
-10% | 1 331
1 351
-1,5% | 2 080
2 094
-0,70% | 2 534
2 424
4,5% | 2 210
2 285
-3,3% |
3 483
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | 1 225
1 369
-11% | 1 330
1 357
-2,0% | 2 079
2 075
0,16% | 2 554
2 543
0,39% | 2 429
2 308
5,3% |
3 586
|
Net income
M $ |
Released
Forecast
Spread | 636
680
-6,5% | 896
894
0,12% | 1 199
1 438
-17% | 2 444
2 257
8,3% | 2 116
1 998
5,9% |
3 172
|
EPS
$ |
Released
Forecast
Spread | 5,52
5,95
-7,2% | 7,70
7,66
0,51% | 10,3
12,6
-18% | 21,3
19,7
7,9% | 18,5
17,6
4,7% |
28,0
| | Announcement Date | 02/09/2016 | 02/09/2017 | 02/08/2018 | 02/06/2019 | 02/06/2020 | |
|
|
|
| Quarterly results | 2018 Q2 | 2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 (e) | 2021 Q1 (e) | 2021 Q2 (e) | 2021 Q3 (e) | 2021 Q4 (e) |
Sales
M $ |
Released
Forecast
Spread | 1 608
1 565
2,7% | 1 663
1 637
1,6% | 1 928
1 729
12% | 1 712
1 763
-2,9% | 1 934
1 802
7,3% | 2 048
1 982
3,4% | 2 170
2 101
3,2% | 1 828
1 811
0,96% | 1 952
1 746
12% | 2 294
2 085
10% |
2 405
|
2 449
|
2 981
|
2 765
|
2 814
|
Operating income
(EBITDA)
M $ |
Released
Forecast
Spread | 763
663
15% | 774
617
25% | 888
622
43% | 644
780
-17% | 879
720
22% | 909
888
2,4% | 989
933
5,9% | 756
867
-13% | 715
890
-20% | 1 112
907
23% |
1 194
|
913
|
903
|
1 078
|
951
|
Operating profit
(EBIT)
M $ |
Released
Forecast
Spread | 622
577
7,8% | 627
591
6,1% | 718
611
18% | 480
637
-25% | 316
162
95% | 739
757
-2,4% | 676
781
-13% | 700
747
-6,3% | 656
714
-8,1% | 1 053
850
24% |
1 027
|
1 062
|
1 099
|
1 137
|
1 158
|
Pre-Tax Profit
(EBT)
M $ |
Released
Forecast
Spread | 656
580
13% | 636
611
4,1% | 676
621
8,9% | 546
642
-15% | 225
197
14% | 769
730
5,2% | 890
795
12% | 669
770
-13% | 919
707
30% | 998
861
16% |
885
|
1 044
|
1 065
|
1 105
|
1 047
|
Net income
M $ |
Released
Forecast
Spread | 551
468
18% | 595
509
17% | 820
590
39% | 461
535
-14% | 193
169
14% | 670
643
4,1% | 792
682
16% | 625
630
-0,93% | 897
596
51% | 842
713
18% |
799
|
958
|
1 094
|
951
|
935
|
EPS
$ |
Released
Forecast
Spread | 4,82
4,02
20% | 5,17
4,43
17% | 7,15
5,32
34% | 3,99
4,63
-14% | 1,68
1,40
20% | 5,86
5,69
2,9% | 6,93
6,18
12% | 5,43
5,50
-1,3% | 7,61
5,07
50% | 7,39
6,35
16% |
7,10
|
9,47
|
13,0
|
9,38
|
9,24
| | Announcement Date | 08/02/2018 | 11/06/2018 | 02/06/2019 | 05/07/2019 | 08/06/2019 | 11/05/2019 | 02/06/2020 | 05/05/2020 | 08/05/2020 | 11/05/2020 | | | | | |
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
© 2021 Factset
|
|
|
|
U.S. hospitals to restrict Lilly COVID-19 antibody treatment due to limited supply |
Net sales (Year) - Rate of surprise
EPS (Year) - Rate of surprise
Net sales (Quarter) - Rate of surprise
EPS (Quarter) - Rate of surprise
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
Previous period
